Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Cut to $3.00 by Analysts at B. Riley

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price trimmed by B. Riley from $4.00 to $3.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also issued reports about the company. Maxim Group dropped their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. D. Boral Capital reissued a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $4.20.

Lineage Cell Therapeutics Price Performance

Lineage Cell Therapeutics stock opened at $0.52 on Friday. The firm has a market capitalization of $114.62 million, a price-to-earnings ratio of -4.33 and a beta of 1.21. The firm has a fifty day simple moving average of $0.60. Lineage Cell Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of LCTX. Fort Sheridan Advisors LLC boosted its position in shares of Lineage Cell Therapeutics by 71.5% in the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the period. Atria Wealth Solutions Inc. purchased a new position in Lineage Cell Therapeutics in the fourth quarter valued at about $29,000. HighTower Advisors LLC boosted its holdings in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after purchasing an additional 19,100 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock valued at $44,000 after purchasing an additional 65,864 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.